Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAP OLIGO study of pembrolizumab-based multidisciplinary therapy for synchronous oligometastatic stage IV non-small cell lung cancer
jRCTs041200046Phase 2Active, not recruiting
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Progression-free survival at 24 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041200046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200046.